Analysts think AURA stock price could increase by 204%
Feb 25, 2025, 12:25 PM
-18.72%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
8 analysts think AURA stock price will increase by 204.48%. The current median analyst target is $22.44 compared to a current stock price of $7.37. The lowest analysts target is $20.20 and the highest analyst target is $24.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
